Entrar Registro gratuito

Panbela Therapeutics EPS

Qual é o EPS de Panbela Therapeutics?

O EPS de Panbela Therapeutics Inc. é 3,051.23

Qual é a definição de EPS?



O lucro por ação (EPS) é a parcela do lucro de uma empresa alocada a cada ação ordinária em circulação. É ajustado para diluição e calculado ao longo de doze meses.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS de empresas na Setor Health Care em NASDAQ em comparação com Panbela Therapeutics

O que Panbela Therapeutics faz?

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Empresas com eps semelhantes a Panbela Therapeutics